|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Steeg PS: Tumor metastasis: mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martin GS: Cell signaling and cancer.
Cancer Cell. 4:167–174. 2003. View Article : Google Scholar
|
|
4
|
Theodosiou A and Ashworth A: MAP kinase
phosphatases. Genome Biol. 3:30092002. View Article : Google Scholar
|
|
5
|
Okudela K, Yazawa T, Woo T, et al:
Down-regulation of DUSP6 expression in lung cancer: its mechanism
and potential role in carcinogenesis. Am J Pathol. 175:867–881.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Furukawa T, Fujisaki R, Yoshida Y, et al:
Distinct progression pathways involving the dysfunction of
DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal
papillary-mucinous neoplasms of the pancreas. Mod Pathol.
18:1034–1042. 2005. View Article : Google Scholar
|
|
7
|
Chan DW, Liu VW, Tsao GS, et al: Loss of
MKP3 mediated by oxidative stress enhances tumorigenicity and
chemoresistance of ovarian cancer cells. Carcinogenesis.
29:1742–1750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wong VC, Chen H, Ko JM, et al: Tumor
suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell
invasion and epithelial-mesenchymal transition (EMT)-associated
phenotype. Int J Cancer. 130:83–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li W, Song L, Ritchie AM and Melton DW:
Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a
molecularly distinct melanoma subtype. Pigment Cell Melanoma Res.
25:188–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang YY, Wu JW and Wang ZX:
Mitogen-activated protein kinase (MAPK) phosphatase 3-mediated
cross-talk between MAPKs ERK2 and p38alpha. J Biol Chem.
286:16150–16162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JU, Huang S, Lee MH, et al: Dual
specificity phosphatase 6 as a predictor of invasiveness in
papillary thyroid cancer. Eur J Endocrinol. 167:93–101. 2012.
View Article : Google Scholar
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
13
|
Yang JL, Lin JH, Weng SW, et al: Crude
extract of Euphorbia formosana inhibits the migration and
invasion of DU145 human prostate cancer cells: The role of matrix
metalloproteinase-2/9 inhibition via the MAPK signaling pathway.
Mol Med Rep. 7:1403–1408. 2013.
|
|
14
|
Lehrer S, Diamond EJ, Mamkine B, Stone NN
and Stock RG: Serum interleukin-8 is elevated in men with prostate
cancer and bone metastases. Technol Cancer Res Treat. 3:4112004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang S, Pettaway CA, Uehara H, Bucana CD
and Fidler IJ: Blockade of NF-kappaB activity in human prostate
cancer cells is associated with suppression of angiogenesis,
invasion and metastasis. Oncogene. 20:4188–4197. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Owens DM and Keyse SM: Differential
regulation of MAP kinase signalling by dual-specificity protein
phosphatases. Oncogene. 26:3203–3213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Keyse SM: Dual-specificity MAP kinase
phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27:253–261.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arnoldussen YJ and Saatcioglu F: Dual
specificity phosphatases in prostate cancer. Mol Cell Endocrinol.
309:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu S, Furukawa T, Kanai N, Sunamura M and
Horii A: Abrogation of DUSP6 by hypermethylation in human
pancreatic cancer. J Hum Genet. 50:159–167. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Furukawa T, Yatsuoka T, Youssef EM, et al:
Genomic analysis of DUSP6, a dual specificity MAP kinase
phosphatase, in pancreatic cancer. Cytogenet Cell Genet.
82:156–159. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Skrzypski M, Dziadziuszko R, Jassem E, et
al: Main histologic types of non-small-cell lung cancer differ in
expression of prognosis-related genes. Clin Lung Cancer.
14:666–673. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Piya S, Kim JY, Bae J, Seol DW, Moon AR
and Kim TH: DUSP6 is a novel transcriptional target of p53 and
regulates p53-mediated apoptosis by modulating expression levels of
Bcl-2 family proteins. FEBS Lett. 586:4233–4240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee H, Kim JM, Huang SM, et al:
Differential expression of DUSP6 with expression of ERK and Ki-67
in non-small cell lung carcinoma. Pathol Res Pract. 207:428–432.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Furukawa T, Sunamura M, Motoi F, Matsuno S
and Horii A: Potential tumor suppressive pathway involving
DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 162:1807–1815. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lim BJ, Jung SS, Choi SY and Lee CS:
Expression of metastasis-associated molecules in non-small cell
lung cancer and their prognostic significance. Mol Med Rep.
3:43–49. 2010.PubMed/NCBI
|
|
26
|
Jin X, Yagi M, Akiyama N, et al:
Matriptase activates stromelysin (MMP-3) and promotes tumor growth
and angiogenesis. Cancer Sci. 97:1327–1334. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu HQ, Song S, Wang JH and Zhang SL:
Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its
clinical significance. Oncol Lett. 2:1319–1322. 2011.PubMed/NCBI
|
|
28
|
Chen Y, Shi M, Yu GZ, et al:
Interleukin-8, a promising predictor for prognosis of pancreatic
cancer. World J Gastroenterol. 18:1123–1129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xie K: Interleukin-8 and human cancer
biology. Cytokine Growth Factor Rev. 12:375–391. 2001. View Article : Google Scholar
|
|
31
|
Inoue K, Slaton JW, Eve BY, et al:
Interleukin 8 expression regulates tumorigenicity and metastases in
androgen-independent prostate cancer. Clin Cancer Res. 6:2104–2119.
2000.PubMed/NCBI
|
|
32
|
Lee LF, Louie MC, Desai SJ, et al:
Interleukin-8 confers androgen-independent growth and migration of
LNCaP: differential effects of tyrosine kinases Src and FAK.
Oncogene. 23:2197–2205. 2004. View Article : Google Scholar
|
